OMER - Omeros' long term data of phase 2 trial of narsoplimab shows benefit in kidney disorder

Omeros (OMER -0.6%) said long term follow up data from a phase 2 trial of its medicine narsoplimab to treat patients with IgA nephropathy, a type of kidney disorder, showed improvement and stabilization in renal function. Previous data from the trial showed that narsoplimab led to median reduction in proteinuria, or excess of protein in the urine, of 64.4%. Now, long-term follow-up (out to 35 months) of these patients shows a markedly slowed rate of decline of estimated glomerular filtration rate ((eGFR)). A 64.4% reduction in proteinuria is predicted to delay progression to renal dialysis by 41.6 years compared to standard of care. The company said narsoplimab-treated patients showed response irrespective of stage of their advanced disease state. The drug was well tolerated with no treatment-related serious adverse events. The data was presented at the Annual Meeting of the American Society of Nephrology.

For further details see:

Omeros' long term data of phase 2 trial of narsoplimab shows benefit in kidney disorder